Recommended

Download our FREE report – Beyond the Lab: Stem cell research
The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing, explore this new webinar and register now!
Secure your place at this exciting upcoming webinar on advancing obesity drug discovery! Register now.
Webinar

Reprogramming immunity: designing smarter checkpoint receptor agonists

28 May 2025

2:00pm

Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.

Autoimmune diseases such as rheumatoid arthritis, lupus, and Sjogren’s syndrome disrupt immune balance, causing the body to attack its own tissues. But what if we could restore that balance – not by shutting down the immune system, but by guiding it back to a state of controlled regulation?

S-4321 is a novel dual-targeting antibody designed to harness the inhibitory signalling of PD-1 on T cells and FcγRIIb on antigen-presenting cells (APCs). By engaging both receptors, S-4321 suppresses excessive immune activation while preserving regulatory T cells, maintaining immune homeostasis without compromising protective immunity.

In this webinar, join Dr Daniela Cipolletta, Senior Director of Immunology at Seismic Therapeutic, as she explores how immune checkpoint dysfunction fuels autoimmune disease. This webinar will also focus on why PD-1 agonism holds the key to controlling T cell activation, but only if done the right way.

Cipolletta will cover how S-4321’s innovative ‘dual-cell’, bidirectional design achieves sustained immune regulation without depleting protective T cells. Additionally, she will explore the surprising role of low-affinity binding in maintaining immune balance.

With compelling data, practical insights, and a fresh approach to immune modulation, this session is designed for researchers, clinicians, and biotech leaders eager to stay ahead in immunotherapy innovation.

Don’t miss this opportunity to explore a smarter way to restore immune homeostasis.

Key learning points: 

  • How S-4321, a novel dual-cell, bidirectional PD-1:FcγRIIb antibody, activates the inhibitory PD-1 receptor on T cells and selectively engages FcγRIIb on APCs to restore immune balance in diseases driven by dysregulated cell-mediated immunity.
  • How the Fab domain of S-4321’s low-affinity binding to PD-1 sustains receptor agonism without causing target depletion or triggering IL-2 production.
  • Why the Fc domain of S-4321’s selective engagement of FcγRIIb prevents depletion of PD-1-expressing T cells (such as Tregs) and reduces proinflammatory cytokine production.

Register now to secure your place >>>

SPEAKER

Dr Daniela Cipolletta

Dr Daniela Cipolletta – Sr. Director of Immunology, Seismic Therapeutic

Dr Daniela Cipolletta is a senior director of immunology for Seismic Therapeutic, a Watertown (MA) based biotech developing a new generation of immunology therapies enabled by machine learning. Daniela has 20 years of immunology focused research with emphasis on bridging immunology with different disease areas including oncology, metabolism, and tissue regeneration. Prior to joining Seismic, Daniela held roles of increasing responsibility at Novartis, where she led and supported several novel immune modulatory programs from early target identification to drug candidate selection and biomarker research. Daniela has also held positions at Amgen and Tempero (a GSK company).

Daniela earned her PhD in Immunology from the European School of Molecular Medicine and completed her post-doctoral training with Drs. Diane Mathis and Christophe Benoist at the Harvard Medical School working on tissue-resident regulatory T cells.

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 28 May at 3pm BST. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.